Several companies have followed Pfizer into CDK2 inhibitor development, but the jury is out on this field’s promise.

Ambrx’s PSMA-targeting ADC generated puzzling data at ESMO, but J&J has seen enough to launch a premium-priced buyout.

A $680m swoop for Harpoon will fill a hole in Merck’s pipeline.

Allogene joins Adicet in going back to the drawing board and scrapping trials in late-line aggressive lymphoma.